Open-Label Extension Study Comparing Latanoprost 0.005% Without vs With Benzalkonium Chloride in Open-Angle Glaucoma or Ocular Hypertension

PURPOSE: To evaluate the long-term safety of latanoprost benzalkonium chloride (BAK)-free vs currently marketed latanoprost 0.005% ophthalmic solution containing BAK (referred to as reference), to treat open-angle glaucoma (OAG) or ocular hypertension (OHT). PATIENTS AND METHODS: This phase 3, multi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen Lee, Bridgitte, Malhotra, Ranjan, Sall, Kenneth, Mitchell, Brittany, Peace, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309311/
https://www.ncbi.nlm.nih.gov/pubmed/35898518
http://dx.doi.org/10.2147/OPTH.S367756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309311/
https://www.ncbi.nlm.nih.gov/pubmed/35898518
http://dx.doi.org/10.2147/OPTH.S367756

Ejemplares similares